Amgen 2025 Q3 Earnings Beats Expectations with 13.6% Net Income Growth

Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Thursday, Nov 6, 2025 10:55 am ET1min read
Aime RobotAime Summary

-

reported Q3 2025 earnings with 12.1% revenue growth to $9.14B and 13.5% EPS increase to $5.98, exceeding expectations.

- Key drivers included strong performance in oncology/inflammation therapies, with Ozanimod ($1.1B) and Otezla ($585M) leading revenue growth.

- Shares rose 5.52% post-earnings as CEO Bradway highlighted R&D investments and market access expansion amid pricing pressures.

- Institutional investors adjusted holdings while analysts praised operational efficiency and strategic manufacturing investments.

Amgen (AMGN) reported Q3 2025 earnings with a 12.1% revenue increase to $9.14 billion and a 13.5% rise in EPS to $5.98, surpassing expectations. , aligning with Q3 results.

Revenue

, driven by robust performance across key therapies. , , respectively. . Other notable segments included Otezla ($585 million), , and Nplate ($457 million). The company also reported $420 million in other revenues, .

Earnings/Net Income

, with net income reaching $3.22 billion—a 13.6% increase from $2.83 billion in 2024 Q3. The EPS growth reflects strong operational efficiency and pricing resilience.

Price Action

Post-earnings,

shares rose 5.52% in the latest trading day, , and 8.75% month-to-date, outperforming broader market trends.

Post-Earnings Price Action Review

, . Analysts highlighted the company’s strategic investments in manufacturing and its resilient portfolio. .

CEO Commentary

CEO Robert A. Bradway emphasized Amgen’s resilience in navigating market dynamics, crediting growth in oncology and inflammation therapies. He acknowledged pricing pressures and competitive challenges but underscored confidence in R&D investments and global market access expansion.

Guidance

, with Q3 results aligning to the upper end of these ranges. .

Additional News

, , . Institutional investors, including NewSquare Capital and First Horizon Advisors, adjusted holdings, . , . , .

, supported by a diversified product portfolio and strategic capital allocation.

Comments



Add a public comment...
No comments

No comments yet